New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pharmaceutical API Manufacturing Global Market Report 2023" - https ...

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

The global biotech API manufacturing services market, valued at US$ 38.9 Billion in 2022, is projected to grow at a CAGR of 7.1% from 2023 to 2031, surpassing US$ 73 Billion by 2031. biotech API ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

Just weeks after announcing a deal to sell its antibiotics manufacturing in the U.S. to Neopharma, India’s Dr. Reddy’s Laboratories says it will now unload its API manufacturing business in Jeedimetla ...

With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play.  | BioDuro, headquartered in ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

Efficiency and adaptability are crucial in the ever-evolving manufacturing industry. As manufacturers adopt advanced technologies like IoT, AI, and cloud computing, the need for seamless integration ...